Drug
Molibresib clinical trials
Also written GSK525762 and GSK-525762A.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
7 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 2
Often tested with
Tested in the same studies.
Itraconazole (1) · Rifampin (1) · Cisplatin (1) · Etoposide (1) · Etoposide phosphate (1) · Entinostat (1) · Trametinib (1)
Studies
Open first, then newest update. How each study uses molibresib is read from its arms, and is right about nine times in ten.
Testing it · 7
- A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic MalignanciesCompletedPhase 2GlaxoSmithKlineNCT01943851Written as GSK525762
- Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast CancerTerminatedPhase 1GlaxoSmithKlineNCT02964507Written as GSK525762
- A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing PotentialCompletedPhase 1GlaxoSmithKlineNCT02706535Written as GSK525762 Besylate Tablets
- Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT CarcinomaWithdrawnPhase 1/2National Cancer Institute (NCI)NCT04116359Written as Molibresib
- Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnPhase 1National Cancer Institute (NCI)NCT03925428Written as Molibresib
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other CancersCompletedPhase 1GlaxoSmithKlineNCT01587703Written as GSK525762
- A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid TumorsWithdrawnPhase 2GlaxoSmithKlineNCT03266159Written as GSK525762 Besylate tablets
Given in every arm · 1 — molibresib is usual care beside what is tested
Codes
What other systems call molibresib · ClinicalTrials.gg INT005756
- MeSH (NLM) C554645molibresibOne source NLM
- UNII (FDA) 5QIO6SRZ2RMOLIBRESIBConfirmed FDA, NLM
- NCI Thesaurus C101538MolibresibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C554645 | molibresib | One source NLM |
| UNII (FDA) | 5QIO6SRZ2R | MOLIBRESIB | Confirmed FDA, NLM |
| NCI Thesaurus | C101538 | Molibresib | One source FDA |
Also registered as molibresib besylate (UNII K04D7I4BCH).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.